ESMO: European Society for Medical Oncology

The latest news from ESMO

  1. EMA Recommends Extension of Indications for Crizotinib

    Two new indications concern the treatment of paediatric patients with ALK-positive anaplastic large cell lymphoma and inflammatory myofibroblastic tumour

  2. EMA Recommends Granting a Conditional Marketing Authorisation for Loncastuximab Tesirine

    It is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma

  3. EMA Recommends Extension of Indications for Axicabtagene Ciloleucel

    New indication concerns the treatment of patients with diffuse large cell lymphoma and high-grade B-cell lymphoma

  4. RNF43 Mutations Warrant Further Validation for Potential to Prioritise Anti-EGFR/BRAF Combinations in Selected Patients with BRAFV600E-Mutated mCRC

    Findings from an assessment of predictive value of RNF43 status in patients with BRAFV600E-mutated metastatic colorectal cancer

  5. EMA Recommends Extension of Indications for Zanubrutinib

    New indication concerns treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy